Piramal Pharma Invests $90 Million in US Facility Expansion Amid Rising Onshoring Trend

Piramal Pharma Limited announces a $90 million expansion of its US facilities in response to increased demand for onshoring drug supply. The investment, aligned with the 'America First' policy, aims to enhance US manufacturing capabilities with new manufacturing space and advanced equipment, boosting the ADC development program, ADCelerate.

In a strategic move to bolster its manufacturing footprint in the United States, Piramal Pharma Limited is set to inject $90 million into expanding its US facilities. This comes as the 'America First' policy underlines the significance of bringing manufacturing jobs back to the home soil.

The company emphasized that the investment comes in response to strong demand from US clients eager to support domestic drug production. The expansions align with Piramal Pharma's commitment to fostering US-based innovation in drug manufacturing.

The expansion will cover new manufacturing spaces and laboratories, enhancing the company's capacity to scale up injectable drug production. Key infrastructural additions include advanced equipment like new filling lines and lyophilizers. As stated, the expanded site is slated for operation by late 2027, further enhancing the ADCelerate program for ADC developments.

(With inputs from agencies.)